SI-BONE(US:SIBN)2025-11-10 21:12Revenue Growth - Worldwide revenue for Q3 2025 was $48.7 million, a 20.6% increase from $40.3 million in Q3 2024[7] - U.S. revenue for Q3 2025 was $46.4 million, reflecting a 21.2% growth from $38.3 million in Q3 2024[7] - The company expects 2025 worldwide revenue to be in the range of $198 million to $200 million, implying year-over-year growth of approximately 18% to 20%[12] Profitability Metrics - Gross margin improved to 79.8% in Q3 2025, up from 79.1% in Q3 2024, representing an improvement of 75 basis points[8] - Adjusted EBITDA was positive at $2.3 million in Q3 2025, compared to an adjusted EBITDA loss of $0.2 million in Q3 2024[10] - Net loss improved by 30.6% to $4.6 million, or $0.11 per diluted share, in Q3 2025, compared to a net loss of $6.6 million, or $0.16 per diluted share, in Q3 2024[10] Operational Highlights - The number of active U.S. physicians increased by 27% to 1,530 in Q3 2025[6] - New Technology Add-on Payment (NTAP) for procedures involving iFuse TORQ TNT is over $4,100 effective October 1, 2025[6] - Operating expenses increased by 11.9% to $44.2 million in Q3 2025, driven by higher revenue and new product rollout[9] Cash Position - Cash and equivalents as of September 30, 2025, were $145.7 million, compared to $145.5 million as of June 30, 2025[11]